Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Executive Officer Agreement (Details)

Executive Officer Agreement (Details) (USD $)	1 Months Ended	3 Months Ended
Executive Officer Agreement (Details) (USD $)	Jan. 07, 2013	Mar. 31, 2013
Executive Officer Agreement (Textual) [Abstract]
Option to purchase common stock grant in period		1,771,590
Common stock, fully-diluted capitalization	6.00%
Option to purchase common stock grant in period exercise price		$ 5.66
Chairman and Chief Executive Officer [Member]
Executive Officer Agreement (Textual) [Abstract]
CEO annual salary	600,000
Option to purchase common stock grant in period	1,686,590
Option to purchase common stock grant in period exercise price	5.57
Description of vesting of stock option grated	One-third of the shares underlying the option will vest on December 28, 2013 and two anniversaries thereafter, subject to Dr. Weisman’s continued employment with the Company.

- Definition

Description of award terms as to how many shares or portion of an award are no longer contingent on satisfaction of either a service condition, market condition or a performance condition, thereby giving the employee the legal right to convert the award to shares, to sell the shares, and be entitled to the cash proceeds of such sale. For example, vesting may be expressed as being 25 percent of the shares under option on each anniversary of the grant date.

+ References + Details